Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Amgen Inc (NASDAQ: AMGN) Delayed: 393.16 +7.51 (1.95%)
Previous Close $385.65    52 Week High $176.85 
Open $385.71    52 Week Low $133.64 
Day High $394.50    P/E 59.21 
Day Low $381.90    EPS $6.64 
Volume 2,714,423